Nasus Pharma Ltd
NSRX
Analytical Summary
Nasus Pharma Ltd faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.
4-Year Financial Trajectory
AnnualBullish Indicators
- No bullish signals detected.
Bearish Risks
- Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile
Health Breakdown
Statement lens
Choose the reporting cadence, isolate a period range, or search directly for a metric.
| Metric | FY 2025 Dec 31, 2025 20-F ↗ | FY 2024 Dec 31, 2024 20-F ↗ | FY 2023 Dec 31, 2023 20-F ↗ | FY 2022 Dec 31, 2022 20-F ↗ |
|---|---|---|---|---|
| EPS Growth YoY (%) |
-227.3%
Weak
Weak
Year-over-year change in earnings per share
Optimal:
> 10%
|
-46.7%
Weak
Weak
Year-over-year change in earnings per share
Optimal:
> 10%
|
— | — |
| Net Income Growth YoY (%) |
-282.2%
Weak
Weak
Year-over-year change in net income |
-45.8%
Weak
Weak
Year-over-year change in net income |
— | — |
| FCF Growth YoY (%) |
-550.7%
Weak
Weak
Year-over-year change in free cash flow |
36.6%
Excellent
Excellent
Year-over-year change in free cash flow |
— | — |
| Metric | FY 2025 Dec 31, 2025 20-F ↗ | FY 2024 Dec 31, 2024 20-F ↗ | FY 2023 Dec 31, 2023 20-F ↗ | FY 2022 Dec 31, 2022 20-F ↗ |
|---|---|---|---|---|
| Operating Margin (%) (%) |
-0.4%
Weak
Weak
Operating income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Below avg (-103%)
|
— | — | — |
| Profit Margin (%) (%) |
-0.5%
Weak
Weak
Net income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Below avg (-104%)
|
— | — | — |
| FCF Margin (%) (%) |
-0.4%
Weak
Weak
Free cash flow as a percentage of revenue
Optimal:
> 10%
|
— | — | — |
| FCF / Net Income (x) |
0.84x
Caution
↑
Caution
Improving
Free cash flow relative to reported net income
Optimal:
> 1x
|
0.43x
Weak
Weak
Free cash flow relative to reported net income
Optimal:
> 1x
|
0.98x
Caution
Caution
Free cash flow relative to reported net income
Optimal:
> 1x
|
— |
| Metric | FY 2025 Dec 31, 2025 20-F ↗ | FY 2024 Dec 31, 2024 20-F ↗ | FY 2023 Dec 31, 2023 20-F ↗ | FY 2022 Dec 31, 2022 20-F ↗ |
|---|---|---|---|---|
| Return on Invested Capital (%) |
-140.0%
Weak
↓
Weak
Declining
Return earned on debt + equity capital invested
Optimal:
> 10%
|
26.5%
Excellent
Excellent
Return earned on debt + equity capital invested
Optimal:
> 10%
|
23.9%
Excellent
Excellent
Return earned on debt + equity capital invested
Optimal:
> 10%
|
— |
| Return on Capital (%) (%) |
-98.0%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
-150.3%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
— | — |
| Return on Common Equity (%) (%) |
-211.6%
Weak
↓
Weak
Declining
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-1510%)
|
47.7%
Excellent
Excellent
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Above avg (+218%)
|
27.7%
Excellent
Excellent
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Above avg (+85%)
|
— |
Secondary lens
Benchmark Lens
Compare NSRX against peers after checking the statement evidence.
Open lens
Benchmark Lens
Compare NSRX against peers after checking the statement evidence.
Signals
Key bullish and bearish indicators for NSRX
No bullish signals detected
Return on Common Equity (%) is in the bottom quartile
Percentile Rankings
How NSRX compares to all companies
Peer Comparison
NSRX vs similar peers
Compare NSRX with peers
Stack NSRX against similar companies across every metric on this page.
north_east Open comparisonbar_chart Data from SEC EDGAR XBRL filings
Synced 1 week ago 4 years · 4 quarters